Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR".

Interestingly, in the context of this clinical success, a clear trend emerged quite early demonstrating that inherent features of TILs and TCR-engineered T cells resulted in durable and complete responses when treating solid cancer [ 11 , 15 , 214 , 215 , 216 ], while, for instance, the “poster child for CAR therapies” [ 217 ], the CD19-directed CAR, led to complete remissions of >88% when treating leukemia and lymphoma in clinical trials.

also in 19,460 other papers